The Future of Pharmaceuticals in the European Union
This article was originally published in SRA
Executive Summary
The European Commission has received a flood of responses to its consultation on the regulatory challenges facing the pharmaceutical sector.Ian Schofield reports on what the regulators themselves think should be done.
You may also be interested in...
Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
Subtracting Rx Adds To Perrigo OTC Pipeline
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
When A Single Shot Is A Problem: J&J’s Study Of Two Doses Raises Equality, Distribution Questions
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: